MedTrace Logo

CLearing Alzheimer's Disease Molecular Pathology Without Medications

NCT04913454 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2021-06-04

No results posted yet for this study

Summary

According to the most popular pathophysiological models of Alzheimer's disease, the amyloid hypothesis, amyloid deposition is the causative event triggering a chain of other downstream events which finally lead to Alzheimer's disease and dementia. In mouse models of Alzheimer's disease, 40 Hz multi-sensory (auditory and visual) stimulation was able to reduce the number and size of amyloid plaques throughout cortex and improve cognitive performance.

The primary objective of this study is to assess whether an intervention consisting of 40 Hz multi-sensory (auditory and visual) stimulation is able to reduce the amyloid load in non-demented amyloid-positive individuals.

As secondary objectives, the investigators will assess whether such intervention is able to:

* improve the brain electrical activity,
* improve or slow down the worsening of Alzheimer's blood-based biomarkers,
* improve or slow down the worsening of cognition.

Conditions

  • Alzheimer Disease
  • Amyloid Plaque
  • Amyloidosis

Interventions

OTHER

40 Hz multi-sensory (auditory + visual) stimulation and cognitive training

40 Hz multi-sensory (auditory + visual) stimulation and cognitive training (1 hour/day, per 5 days/week, for a total of 8 weeks)

OTHER

Cognitive training

Cognitive training (1 hour/day, per 5 days/week, for a total of 8 weeks)

Sponsors & Collaborators

  • University Hospital, Geneva

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-08-01
Primary Completion
2022-06-30
Completion
2022-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04913454 on ClinicalTrials.gov